The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain

Molecular Mechanisms of REM Sleep

(2020) Rikuhiro G. Yamada et al.   Frontiers in Neuroscience

TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys

(2019) Emi Kurimoto et al.   PLoS One

Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders

(2019) Daniel Erskine et al.   DRUG DISCOVERY TODAY

Ketamine effects on default mode network activity and vigilance: A randomized, placebo‐controlled crossover simultaneous fMRI/EEG study

(2019) Norman Zacharias et al.   HUMAN BRAIN MAPPING

Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: A placebo controlled, cross-over study

(2019) Claudia Vingerhoets et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

Neural oscillations during cognitive processes in an App knock-in mouse model of Alzheimer’s disease pathology

(2019) Sofia Jacob et al.   Scientific Reports

NMDA receptors on parvalbumin-positive interneurons and pyramidal neurons both contribute to MK-801 induced gamma oscillatory disturbances: Complex relationships with behaviour

(2019) Matthew R. Hudson et al.   NEUROBIOLOGY OF DISEASE

Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders

(2019) Sean P. Moran et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy

(2018) Stuti Verma et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases

(2018) Christian C. Felder et al.   NEUROPHARMACOLOGY

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects

(2018) Mitul A. Mehta et al.   PSYCHOPHARMACOLOGY

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders

(2018) Daniel C. Javitt et al.   JAMA Psychiatry

Ten-Hour Exposure to Low-Dose Ketamine Enhances Corticostriatal Cross-Frequency Coupling and Hippocampal Broad-Band Gamma Oscillations

(2018) Tony Ye et al.   Frontiers in Neural Circuits

Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline

(2018) Catherine A. Thorn et al.   ACS Chemical Neuroscience

Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity

(2017) A. Ahnaou et al.   Translational Psychiatry

Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia

(2017) Daniel C. Javitt et al.   SCHIZOPHRENIA RESEARCH

Large-scale functional connectivity networks in the rodent brain

(2016) Alessandro Gozzi et al.   NEUROIMAGE

State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects

(2016) Robert W. Gould et al.   NEUROPHARMACOLOGY

Species-conserved reconfigurations of brain network topology induced by ketamine

(2016) R Becker et al.   Translational Psychiatry

N-Methyl-D-Aspartate Receptor Antagonist Effects on Prefrontal Cortical Connectivity Better Model Early Than Chronic Schizophrenia

(2015) Alan Anticevic et al.   BIOLOGICAL PSYCHIATRY

Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans

(2015) Suresh D. Muthukumaraswamy et al.   JOURNAL OF NEUROSCIENCE

Ketamine interactions with biomarkers of stress: A randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men

(2015) Najmeh Khalili-Mahani et al.   NEUROIMAGE

Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI

(2015) Disha Shah et al.   NEUROIMAGE

Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice

(2015) Mark J. Hunt et al.   PSYCHOPHARMACOLOGY

Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile

(2015) R. Joules et al.   PSYCHOPHARMACOLOGY

A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice

(2015) F Errico et al.   Translational Psychiatry

High frequency oscillations are associated with cognitive processing in human recognition memory

(2014) Michal T. Kucewicz et al.   BRAIN

Cholinergic circuit modulation through differential recruitment of neocortical interneuron types during behaviour

(2014) Rogier B. Poorthuis et al.   JOURNAL OF PHYSIOLOGY-LONDON

Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior

(2014) Yang Zhan et al.   NATURE NEUROSCIENCE

Studying Brain Organization via Spontaneous fMRI Signal

(2014) Jonathan D. Power et al.   NEURON

Losing Control Under Ketamine: Suppressed Cortico-Hippocampal Drive Following Acute Ketamine in Rats

(2014) Rosalyn J Moran et al.   NEUROPSYCHOPHARMACOLOGY

Dissociable Effects of Antipsychotics on Ketamine-Induced Changes in Regional Oxygenation and Inter-Regional Coherence of Low Frequency Oxygen Fluctuations in the Rat

(2014) Jennifer Li et al.   NEUROPSYCHOPHARMACOLOGY

Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

(2014) Nellie E Byun et al.   NEUROPSYCHOPHARMACOLOGY

Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease

(2013) Bruce J. Melancon et al.   DRUG DISCOVERY TODAY

Distributed BOLD and CBV-weighted resting-state networks in the mouse brain

(2013) Francesco Sforazzini et al.   NEUROIMAGE

The Muscarinic Acetylcholine Receptor Agonist BuTAC Mediates Antipsychotic-Like Effects via the M4 Subtype

(2013) Marla L Watt et al.   NEUROPSYCHOPHARMACOLOGY

Sub-Anesthetic Ketamine Modulates Intrinsic BOLD Connectivity Within the Hippocampal-Prefrontal Circuit in the Rat

(2013) Natalia Gass et al.   NEUROPSYCHOPHARMACOLOGY

Test–retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers

(2012) S. De Simoni et al.   NEUROIMAGE

Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior

(2012) Marina R. Picciotto et al.   NEURON

Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline

(2011) Dong Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia

(2011) Segev Barak et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A robust experimental protocol for pharmacological fMRI in rats and mice

(2011) Livia Ferrari et al.   JOURNAL OF NEUROSCIENCE METHODS

Differential effects of NMDA antagonists on high frequency and gamma EEG oscillations in a neurodevelopmental model of schizophrenia

(2011) K.G. Phillips et al.   NEUROPHARMACOLOGY

Electroencephalographic Spectral and Coherence Analysis of Ketamine in Rats: Correlation with Behavioral Effects and Pharmacokinetics

(2011) Tomáš Páleníček et al.   NEUROPSYCHOBIOLOGY

The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action

(2011) Giovanni Martino et al.   PAIN

A Neural Switch for Active and Passive Fear

(2010) Alessandro Gozzi et al.   NEURON

A novel derivative of xanomeline improves fear cognition in aged mice

(2010) Wen Si et al.   NEUROSCIENCE LETTERS

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

(2008) Anantha Shekhar et al.   AMERICAN JOURNAL OF PSYCHIATRY

Glutamate and the Neural Basis of the Subjective Effects of Ketamine

(2008) J. F. William Deakin et al.   ARCHIVES OF GENERAL PSYCHIATRY

Projections of the paraventricular and paratenial nuclei of the dorsal midline thalamus in the rat

(2008) Robert P. Vertes et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?

(2008) Elizabeth Scarr et al.   JOURNAL OF NEUROCHEMISTRY

Drug–anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine

(2008) Alessandro Gozzi et al.   MAGNETIC RESONANCE IMAGING

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

(2008) W. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat

(2008) Alessandro Gozzi et al.   PSYCHOPHARMACOLOGY

Cholinergic control of GABA release: emerging parallels between neocortex and hippocampus

(2008) J. Josh Lawrence   TRENDS IN NEUROSCIENCES

A novel derivative of xanomeline improved memory function in aged mice

(2008) Yi-Hui Cui et al.   Neuroscience Bulletin

Muscarinic acetylcholine receptors as CNS drug targets

(2007) Christopher J. Langmead et al.   PHARMACOLOGY & THERAPEUTICS